Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12260992 | 0.89 | MMP2 (0.47) | MMP2KEAP1KDM4EHPGDALDH1A1 | |
| SCHEMBL16144436 | 0.85 | MMP2 (0.53) | MMP2KEAP1KDM4EHPGDALDH1A1 | |
| SCHEMBL6371982 | 0.84 | KDM4E (0.64) | KEAP1KDM4EHPGDALDH1A1TP53 | |
| SCHEMBL12261000 | 0.81 | MMP2 (0.53) | MMP2KDM4EHPGDALDH1A1TP53 | |
| SCHEMBL2941369 | 0.81 | HPGD (0.56) | KEAP1KDM4EHPGDALDH1A1TP53 | |
| SCHEMBL1706450 | 0.80 | MMP2 (0.60) | MMP2KEAP1ALDH1A1HSD17B10CCR6 | |
| SCHEMBL3309142 | 0.79 | ALB (0.55) | KEAP1HPGDALDH1A1TP53TDP1 | |
| SCHEMBL3312574 | 0.79 | KEAP1 (0.49) | KEAP1HPGDALDH1A1TP53TDP1 | |
| SCHEMBL12261033 | 0.79 | MMP2 (0.50) | MMP2KDM4EHPGDALDH1A1TP53 | |
| SCHEMBL29478348 | 0.78 | TSHR (0.62) | KEAP1KDM4EHPGDALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3668832-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | Allergan, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
| US-8183281-B2 | CXC-chemokine receptor ligands | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| EP-2155670-B1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2155670-A1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148790-A1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | CXCR2, CXCR1, CX3CR1 | MMP2 932/4885KEAP1 1025/4885KDM4E 4653/4885 |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | MMP2 4526/4885KEAP1 287/4885KDM4E 2677/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | MMP2 4526/4885KEAP1 287/4885KDM4E 2677/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | MMP2 4526/4885KEAP1 287/4885KDM4E 2677/4885 |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | MMP2 4526/4885KEAP1 287/4885KDM4E 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.